PMID- 38094114
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231214
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 10
DP  - 2023
TI  - Multicenter registry and test bed for extended outpatient hemodynamic monitoring: 
      the hemodynamic frontiers in heart failure (HF(2)) initiative.
PG  - 1321415
LID - 10.3389/fcvm.2023.1321415 [doi]
LID - 1321415
AB  - BACKGROUND: Hemodynamic Frontiers in Heart Failure (HF(2)) is a multicenter 
      academic research consortium comprised of 14 US institutions with mature remote 
      monitoring programs for ambulatory patients with heart failure (HF). The 
      consortium developed a retrospective and prospective registry of patients 
      implanted with a wireless pulmonary artery pressure (PAP) sensor. GOALS/AIMS: 
      HF(2) registry collects demographic, clinical, laboratory, echocardiographic 
      (ECHO), and hemodynamic data from patients with PAP sensors. The aims of HF(2) 
      are to advance understanding of HF and to accelerate development of novel 
      diagnostic and therapeutic innovations. METHODS: HF(2) includes adult patients 
      implanted with a PAP sensor as per FDA indications (New York Heart Association 
      (NYHA) Class III HF functional class with a prior hospitalization, or patients 
      with NYHA Class II or brain natriuretic peptide (BNP) elevation without 
      hospitalization) at a HF(2) member site between 1/1/19 to present. HF(2) registry 
      is maintained at University of Kansas Medical Center (KUMC). The registry was 
      approved by the institutional review board (IRB) at all participating 
      institutions with required data use agreements. Institutions report data into the 
      electronic registry database using REDCap, housed at KUMC. RESULTS: This initial 
      data set includes 254 patients implanted from the start of 2019 until May 2023. 
      At time of device implant, the cohort average age is 73 years old, 59.8% are 
      male, 72% have NYHA Class III HF, 40% have left ventricular ejection fraction 
      (LVEF) < 40%, 35% have LVEF > 50%, mean BNP is 560 pg/ml, mean N-Terminal pro-BNP 
      (NTproBNP) is 5,490 pg/ml, mean creatinine is 1.65 mg/dl. Average baseline 
      hemodynamics at device implant are right atrial pressure (RAP) of 11 mmHg, 
      pulmonary artery systolic pressure (PASP) of 47 mmHg, pulmonary artery diastolic 
      pressure (PADP) 21 mmHg, mean pulmonary artery pressure (mPAP) of 20 mmHg, 
      pulmonary capillary wedge pressure (PCWP) of 19 mmHg, cardiac output (CO) of 
      5.3 L/min, and cardiac index (CI) of 2.5 L/min/m(2). CONCLUSION: A real-world 
      registry of patients implanted with a PAP sensor enables long-term evaluation of 
      hemodynamic and clinic outcomes in highly-phenotyped ambulatory HF patients, and 
      creates a unique opportunity to validate and test novel diagnostic and 
      therapeutic approaches to HF.
CI  - (c) 2023 Heywood, Munshi, Jordan, Muse, Fudim, Sauer, McDermott, Shah, Bhimaraj, 
      Khedraki, Robinson, McCann, Volz, Guha, Jonsson, Bhatt, Bennett, Benjamin, Guglin 
      and Abraham.
FAU - Heywood, J Thomas
AU  - Heywood JT
AD  - Division of Cardiovascular Medicine, Scripps Clinic, Prebys Cardiovascular 
      Institute, La Jolla, CA, United States.
FAU - Munshi, Kartik
AU  - Munshi K
AD  - Department of Cardiovascular Medicine, University of Kansas Medical Center, 
      Kansas City, KS, United States.
FAU - Jordan, Timothy
AU  - Jordan T
AD  - Division of Cardiovascular Medicine, Scripps Clinic, Prebys Cardiovascular 
      Institute, La Jolla, CA, United States.
FAU - Muse, Evan
AU  - Muse E
AD  - Division of Cardiovascular Medicine, Scripps Clinic, Prebys Cardiovascular 
      Institute, La Jolla, CA, United States.
FAU - Fudim, Marat
AU  - Fudim M
AD  - Division of Cardiology, Duke Medical Center, Durham, NC, United States.
FAU - Sauer, Andrew J
AU  - Sauer AJ
AD  - Saint Luke's Mid America Heart Inst, Kansas City, MO, United States.
FAU - McDermott, Margaret
AU  - McDermott M
AD  - Division of Cardiovascular Medicine, Scripps Clinic, Prebys Cardiovascular 
      Institute, La Jolla, CA, United States.
FAU - Shah, Hirak
AU  - Shah H
AD  - Department of Cardiovascular Medicine, University of Kansas Medical Center, 
      Kansas City, KS, United States.
FAU - Bhimaraj, Arvind
AU  - Bhimaraj A
AD  - Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, 
      Houston, TX, United States.
FAU - Khedraki, Rola
AU  - Khedraki R
AD  - Division of Cardiovascular Medicine, Scripps Clinic, Prebys Cardiovascular 
      Institute, La Jolla, CA, United States.
FAU - Robinson, Monique R
AU  - Robinson MR
AD  - University Hospital Health System, Cleveland, OH, United States.
FAU - McCann, Patrick
AU  - McCann P
AD  - PRISMA Health, Columbia, SC, United States.
FAU - Volz, Elizabeth
AU  - Volz E
AD  - Division of Cardiology, UNC Rex Healthcare, Raleigh, NC, United States.
FAU - Guha, Ashrith
AU  - Guha A
AD  - Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, 
      Houston, TX, United States.
FAU - Jonsson, Orvar
AU  - Jonsson O
AD  - Sanford Cardiovascular Institute, Sioux Falls, SD, United States.
FAU - Bhatt, Kunjan A
AU  - Bhatt KA
AD  - Department of Heart Failure, Austin Heart PA, Austin, TX, United States.
FAU - Bennett, Mosi K
AU  - Bennett MK
AD  - Allina Health Minneapolis Heart Institute, Minneapolis, MN, United States.
FAU - Benjamin, Terrie Ann
AU  - Benjamin TA
AD  - Heart Failure Division, M Health Fairview St. Joseph's Hospital, St. Paul, MN, 
      United States.
FAU - Guglin, Maya
AU  - Guglin M
AD  - Indiana University, Indianapolis, IN, United States.
FAU - Abraham, Jacob
AU  - Abraham J
AD  - Center for Cardiovascular Analytics, Research, and Data Science (CARDS), 
      Providence St. Joseph Research Network, Portland, OR, United States.
LA  - eng
PT  - Journal Article
DEP - 20231129
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC10716259
OTO - NOTNLM
OT  - CardioMEMS
OT  - heart failure
OT  - hemodynamics
OT  - pulmonary artery pressure
OT  - pulmonary hypertension
OT  - remote monitoring
COIS- TH received honoraria from Johnson and Johnson, United Therapeutics, Boehringer 
      Ingelheim, Bayer, Lily as well as research grant support from Johnson and 
      Johnson. JA is a consultant for Abiomed and Abbott, and is on the speaker's 
      bureau for Abiomed, Abbott, Ancora. MF is a speaker for Abbott. AS disclosures 
      include consulting for or receiving research funding from Abbott, Boston 
      Scientific, Medtronic, Biotronik, Impulse Dynamics, Acorai, General Prognostics, 
      Edwards Lifesciences, Story Health, Bayer, CSL Vifor. HS is a consultant for 
      Endotronix and a speaker for Impulse Dynamics. AB is a consultant for Abbott. PM 
      is a consultant for Abbott, AstraZeneca, Janssen, Daxor, and CVRx. OJ is a 
      speaker for Abbott. KB is on the speaker's bureau for Abbott, Pfizer, and 
      Novartis and is a consultant for Abbott and Vectorius. MB is a consultant for 
      Abbott and Rhythm Management Group. TAB is a consultant for Abbott. The remaining 
      authors declare that the research was conducted in the absence of any commercial 
      or financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2023/12/14 06:42
MHDA- 2023/12/14 06:43
PMCR- 2023/01/01
CRDT- 2023/12/14 04:10
PHST- 2023/10/14 00:00 [received]
PHST- 2023/11/13 00:00 [accepted]
PHST- 2023/12/14 06:43 [medline]
PHST- 2023/12/14 06:42 [pubmed]
PHST- 2023/12/14 04:10 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2023.1321415 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2023 Nov 29;10:1321415. doi: 10.3389/fcvm.2023.1321415. 
      eCollection 2023.